Figure 6.

Erastin and sorafenib could induce ferroptosis in clear cell renal cell carcinoma cells. (a) Cell viability was determined by CCK-8 assay. Erastin could inhibit the growth of 769-P (i), while ferrostain-1 partially blocks this (iii). Sorafenib could inhibit the growth of CAKI-1 (ii), while ferrostain-1 partially blocks this (iv). (b) Iron concentration was measured with an Iron Assay kit. Erastin and sorafenib could increase the iron concentration of 769-P and CAKI-1. (c) GSH content in cell lysates was assayed by Total Glutathione Quantification Kit. Erastin and sorafenib could increase the GSH consumption of 769-P and CAKI-1. (d) The ferrostain-1 could recover the influence of erastin and sorafenib on the iron concentration and GSH consumption of CAKI-1 (i) and 769-P (ii).